title: [Primary hyperaldosteronism].
abstract: The diagnosis of primary aldosteronism (PA) is based on the finding of the combination of elevated urinary and/or plasma aldosterone and suppressed renin activity in patients with hypertension and hypokalemia. However, PA consists in a number of subsets, and diagnostic criteria for a correct identification of surgically remediable forms are of great interest. The methods and the results concerning our series of 113 patients with primary aldosteronism are presented in this review. Aldosterone producing adenoma (APA) and idiopathic hyperaldosteronism (IHA) were the most frequent forms, 51% and 44% respectively. They had similar BP levels, but hypokalemia was most frequently found in APA. Urinary and upright plasma aldosterone were similar, but supine plasma aldosterone was lower in IHA. Plasma aldosterone response to upright posture and angiotensin II infusion was absent in most cases of APA and present in IHA, but occasionally renin-responsive adenoma were found. Captopril failed to decrease plasma aldosterone in most patients with APA, and in a subgroup of patients with IHA. Patients with adenoma had also higher values of the aldosterone precursor 18-OH-B, and of atrial natriuretic peptide (ANP), probably as a consequence of a greater degree of volume expansion. Among morphological studies, CT scan and adrenal radio-cholesterol scintiscan provided similar results (85% accuracy): adrenal vein catheterization clarified almost all the remaining cases. Among the subsets of PA, 3 familiar cases of dex-suppressible hyperaldosteronism were recognized, with characteristically high levels of aldo, 18-OH-B, 18-OH-cortisol and 18-oxo-cortisol, due to the genetic abnormalities of the 11-18 hydroxylase system.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Istituto di Semeiotica Medica, Università degli Studi, Padova.
authors.forename: G
authors.initials: G
authors.lastname: Opocher
authors.forename: S
authors.initials: S
authors.lastname: Rocco
authors.forename: G
authors.initials: G
authors.lastname: Carpené
authors.forename: D
authors.initials: D
authors.lastname: Armanini
authors.forename: F
authors.initials: F
authors.lastname: Mantero
mesh_terms: D000236:Adenoma / Q000150:complications; D000302:Adrenal Cortex / Q000473:pathology; D000306:Adrenal Cortex Neoplasms / Q000150:complications; D009320:Atrial Natriuretic Factor / Q000378:metabolism; D002216:Captopril / Q000494:pharmacology / Q000627:therapeutic use; D002277:Carcinoma / Q000150:complications; D019405:Cytochrome P-450 CYP11B2; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics; D003907:Dexamethasone; D003952:Diagnostic Imaging; D006801:Humans; D006929:Hyperaldosteronism / Q000175:diagnosis / Q000201:enzymology / Q000209:etiology / Q000473:pathology / Q000628:therapy; D006965:Hyperplasia; D011187:Posture; D012083:Renin / Q000097:blood; D012189:Retrospective Studies; D013252:Steroid 11-beta-Hydroxylase / Q000235:genetics
chemical_list: D003907:Dexamethasone; D009320:Atrial Natriuretic Factor; D003577:Cytochrome P-450 Enzyme System; D002216:Captopril; D019405:Cytochrome P-450 CYP11B2; D013252:Steroid 11-beta-Hydroxylase; D012083:Renin
vernacular_title: Iperaldosteronismo primitivo.